Cargando…

Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors

OBJECTIVE: We compared functional impairment outcomes assessed with Sheehan Disability Scale (SDS) after treatment with duloxetine versus selective serotonin reuptake inhibitors (SSRIs) in patients with major depressive disorder. METHODS: Data were pooled from four randomized studies comparing treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheehan, David V., Mancini, Michele, Wang, Jianing, Berggren, Lovisa, Cao, Haijun, Dueñas, Héctor José, Yue, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049604/
https://www.ncbi.nlm.nih.gov/pubmed/26331440
http://dx.doi.org/10.1002/hup.2500
_version_ 1782457749480669184
author Sheehan, David V.
Mancini, Michele
Wang, Jianing
Berggren, Lovisa
Cao, Haijun
Dueñas, Héctor José
Yue, Li
author_facet Sheehan, David V.
Mancini, Michele
Wang, Jianing
Berggren, Lovisa
Cao, Haijun
Dueñas, Héctor José
Yue, Li
author_sort Sheehan, David V.
collection PubMed
description OBJECTIVE: We compared functional impairment outcomes assessed with Sheehan Disability Scale (SDS) after treatment with duloxetine versus selective serotonin reuptake inhibitors (SSRIs) in patients with major depressive disorder. METHODS: Data were pooled from four randomized studies comparing treatment with duloxetine and SSRIs (three double blind and one open label). Analysis of covariance, with last‐observation‐carried‐forward approach for missing data, explored treatment differences between duloxetine and SSRIs on SDS changes during 8 to 12 weeks of acute treatment for the intent‐to‐treat population. Logistic regression analysis examined the predictive capacity of baseline patient characteristics for remission in functional impairment (SDS total score ≤ 6 and SDS item scores ≤ 2) at endpoint. RESULTS: Included were 2193 patients (duloxetine n = 1029; SSRIs n = 835; placebo n = 329). Treatment with duloxetine and SSRIs resulted in significantly (p < 0.01) greater improvements in the SDS total score versus treatment with placebo. Higher SDS (p < 0.0001) or 17‐item Hamilton Depression Rating Scale baseline scores (p < 0.01) predicted lower probability of functional improvement after treatment with duloxetine or SSRIs. Female gender (p ≤ 0.05) predicted higher probability of functional improvement after treatment with duloxetine or SSRIs. CONCLUSIONS: Treatment with SSRIs and duloxetine improved functional impairment in patients with major depressive disorder. Higher SDS or 17‐item Hamilton Depression Rating Scale baseline scores predicted less probability of SDS improvement; female gender predicted better improvement in functional impairment at endpoint. © 2015 The Authors. Human Psychopharmacology: Clinical and Experimental published by John Wiley & Sons, Ltd.
format Online
Article
Text
id pubmed-5049604
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50496042016-10-06 Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors Sheehan, David V. Mancini, Michele Wang, Jianing Berggren, Lovisa Cao, Haijun Dueñas, Héctor José Yue, Li Hum Psychopharmacol Research Articles OBJECTIVE: We compared functional impairment outcomes assessed with Sheehan Disability Scale (SDS) after treatment with duloxetine versus selective serotonin reuptake inhibitors (SSRIs) in patients with major depressive disorder. METHODS: Data were pooled from four randomized studies comparing treatment with duloxetine and SSRIs (three double blind and one open label). Analysis of covariance, with last‐observation‐carried‐forward approach for missing data, explored treatment differences between duloxetine and SSRIs on SDS changes during 8 to 12 weeks of acute treatment for the intent‐to‐treat population. Logistic regression analysis examined the predictive capacity of baseline patient characteristics for remission in functional impairment (SDS total score ≤ 6 and SDS item scores ≤ 2) at endpoint. RESULTS: Included were 2193 patients (duloxetine n = 1029; SSRIs n = 835; placebo n = 329). Treatment with duloxetine and SSRIs resulted in significantly (p < 0.01) greater improvements in the SDS total score versus treatment with placebo. Higher SDS (p < 0.0001) or 17‐item Hamilton Depression Rating Scale baseline scores (p < 0.01) predicted lower probability of functional improvement after treatment with duloxetine or SSRIs. Female gender (p ≤ 0.05) predicted higher probability of functional improvement after treatment with duloxetine or SSRIs. CONCLUSIONS: Treatment with SSRIs and duloxetine improved functional impairment in patients with major depressive disorder. Higher SDS or 17‐item Hamilton Depression Rating Scale baseline scores predicted less probability of SDS improvement; female gender predicted better improvement in functional impairment at endpoint. © 2015 The Authors. Human Psychopharmacology: Clinical and Experimental published by John Wiley & Sons, Ltd. John Wiley and Sons Inc. 2016-01 2015-09-01 /pmc/articles/PMC5049604/ /pubmed/26331440 http://dx.doi.org/10.1002/hup.2500 Text en © 2015 The Authors. Human Psychopharmacology: Clinical and Experimental published by John Wiley & Sons, Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Sheehan, David V.
Mancini, Michele
Wang, Jianing
Berggren, Lovisa
Cao, Haijun
Dueñas, Héctor José
Yue, Li
Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors
title Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors
title_full Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors
title_fullStr Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors
title_full_unstemmed Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors
title_short Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors
title_sort assessment of functional outcomes by sheehan disability scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049604/
https://www.ncbi.nlm.nih.gov/pubmed/26331440
http://dx.doi.org/10.1002/hup.2500
work_keys_str_mv AT sheehandavidv assessmentoffunctionaloutcomesbysheehandisabilityscaleinpatientswithmajordepressivedisordertreatedwithduloxetineversusselectiveserotoninreuptakeinhibitors
AT mancinimichele assessmentoffunctionaloutcomesbysheehandisabilityscaleinpatientswithmajordepressivedisordertreatedwithduloxetineversusselectiveserotoninreuptakeinhibitors
AT wangjianing assessmentoffunctionaloutcomesbysheehandisabilityscaleinpatientswithmajordepressivedisordertreatedwithduloxetineversusselectiveserotoninreuptakeinhibitors
AT berggrenlovisa assessmentoffunctionaloutcomesbysheehandisabilityscaleinpatientswithmajordepressivedisordertreatedwithduloxetineversusselectiveserotoninreuptakeinhibitors
AT caohaijun assessmentoffunctionaloutcomesbysheehandisabilityscaleinpatientswithmajordepressivedisordertreatedwithduloxetineversusselectiveserotoninreuptakeinhibitors
AT duenashectorjose assessmentoffunctionaloutcomesbysheehandisabilityscaleinpatientswithmajordepressivedisordertreatedwithduloxetineversusselectiveserotoninreuptakeinhibitors
AT yueli assessmentoffunctionaloutcomesbysheehandisabilityscaleinpatientswithmajordepressivedisordertreatedwithduloxetineversusselectiveserotoninreuptakeinhibitors